Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.
Plasma exchange and administration of intravenous immunoglobulin (IgG) are established treatments for Guillain-Barré syndrome (GBS). Elimination of postulated pathogenetic factors by plasma exchange or selective adsorption treatment using affinity-type adsorption columns and subsequent immunomodulation by intravenous IgG may provide a more effective treatment. Forty-five patients with acute GBS were prospectively examined using a clinical score. We treated 11 patients by plasma exchange, 13 patients by selective adsorption using a tryptophan-linked polyvinyl alcohol gel adsorbent, and 21 patients by selective adsorption followed by intravenous IgG. The patients treated sequentially by selective adsorption and intravenous IgG improved significantly better than the patients who received plasma treatment only. The results suggest that sequential treatment of GBS may be superior to plasma treatment alone. The higher cost of combined treatment may be offset by lower overall expenditure.
Haupt
W F
WF
Department of Neurology, University of Cologne, Germany.
Rosenow
F
F
van der Ven
C
C
Borberg
H
H
Pawlik
G
G
D000208:Acute Disease; D003131:Combined Modality Therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007163:Immunosorbent Techniques; D010951:Plasma Exchange / Q000379:methods; D011129:Polyradiculoneuropathy / Q000628:therapy*; D011446:Prospective Studies; D013997:Time Factors
D016756:Immunoglobulins, Intravenous